This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/national-drug-code-directory/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/chemspider/
n23http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n25http://www.rxlist.com/cgi/generic/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
n19http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/pubchem-compound/
n6http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00885/identifier/drugbank/

Statements

Subject Item
n2:DB00885
rdf:type
n3:Drug
n3:description
Pemirolast potassium is a slightly yellow powder that is soluble in water. It is a mast cell stabilizer that acts as an antiallergic agent. As an ophthalmic aqueous sterile solution, pemirolast is used for the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis. Pemirolast is potentially useful for prophylaxis of pulmonary hypersensitivity reactions to drugs such as paclitaxel.
n3:generalReferences
# Tinkelman DG, Berkowitz RB: A pilot study of pemirolast in patients with seasonal allergic rhinitis. Ann Allergy. 1991 Feb;66(2):162-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1994787
n3:group
approved
n3:halfLife
4.5 hours (Ophthalmic)
n3:indication
For the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis
n3:manufacturer
n17:271B5808-363D-11E5-9242-09173F13E4C5
owl:sameAs
n22:DB00885 n23:DB00885
dcterms:title
Pemirolast
adms:identifier
n9:51990 n10:DB00885 n11:PA164781018 n12:Pemirolast n13:46509034 n15:57697 n16:D01088 n18:68669-711-10
n3:mechanismOfAction
Pemirolast binds to the histamine H<sub>1</sub> receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Pemirolast has also been observed to inhibit antigen-stimulated calcium ion influx into mast cells through the blockage of calcium channels. Pemirolast inhibits the chemotaxis of eosinophils into ocular tissue, and prevents inflammatory mediator release from human eosinophils.
n3:packager
n17:271B5807-363D-11E5-9242-09173F13E4C5 n17:271B5806-363D-11E5-9242-09173F13E4C5
n3:patent
n7:5034230
n3:routeOfElimination
Following topical administration, about 10-15% of the dose was excreted unchanged in the urine.
n3:synonym
Pemirolastum Pemirolast Pemirox Pemirolast
n3:salt
n3:synthesisReference
Graziano Castaldi, "Process for the preparation of high purity pemirolast." U.S. Patent US20030032805, issued February 13, 2003.
n19:hasConcept
n20:M0155363
foaf:page
n6:pemirolast.html n25:alamast.htm
n3:IUPAC-Name
n4:271B580E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5814-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5813-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5810-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5811-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5812-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B580C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5824-363D-11E5-9242-09173F13E4C5 n4:271B580D-363D-11E5-9242-09173F13E4C5 n4:271B580A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B580B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B581A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B581B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5815-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5816-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5818-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5817-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5819-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
100299-08-9
n3:category
n3:containedIn
n24:271B5809-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5820-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5822-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5823-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B581F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B581E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5821-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B580F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B581C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B581D-363D-11E5-9242-09173F13E4C5